An early study demonstrated that co-targeted PI3K and MEK signaling pathways enhanced cytotoxicity of histone deacetylase inhibitors in NSCLC and chronic myeloid leukemia[35]. The gene discussed is MAP2K7; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.